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Abstract
Since the first description of COVID-19 in December 2019, more than 63,000 publications have 
described its virology, clinical course, management, treatment and prevention. Most physicians 
are now encountering, or will soon encounter, patients with COVID-19 and must attempt to 
simultaneously assimilate this avalanche of information while managing an entirely novel disease 
with few guiding precedents. 
It is increasingly clear that, although primarily a respiratory illness, COVID-19 is associated with 
cardiovascular complications. However, the true incidence of direct cardiac complications 
remains unclear, as all complications thus far reported can also occur in patients without COVID-
19.
In this review, we briefly summarise and critically appraise the data on cardiac complications 
associated with COVID-19 and describe some cases from our own experience. We identify 
unresolved questions and highlight the many uncertainties in this developing field.
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Introduction
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV2), was first reported in Wuhan in China in the autumn of 2019. It rapidly 
disseminated to cause a pandemic declared by the World Health Organization in March 2020, 
which the world continues to struggle against.
By May 2020, multiple case reports (1-13) and descriptions on social media suggested COVID-
19 is associated with a range of cardiac complications. At the time of first submission of this 
review, a PubMed search of “COVID” and “Cardiovascular” yielded 653 studies; this had 
increased to 3,055 by the time of final submission. A number of excellent reviews already describe 
the potential cardiac complications of COVID-19 (14-18). However, new data is emerging 
constantly, justifying our attempt to put this literature into context alongside our own clinical 
experience.
It is still challenging to define the true incidence of cardiac complications, and particularly to 
determine what proportion relates specifically to COVID-19, rather than more generally to critical 
illness or even coincidence. Any disease with a substantial mortality that may require invasive 
ventilatory and circulatory support is associated with cardiac complications such as 
cardiomyopathy, myocardial infarction, arrhythmia, hypotension and heart failure, particularly in 
patients with pre-existing conditions placing them at higher risk. The distinction between direct 
and indirect causation of cardiac complications is important in considering what treatment or 
management may improve outcomes.
We and colleagues serve a 1000-bed hospital with tertiary services for both infectious diseases 
and cardiology which had treated over 1450 COVID-19 cases by May 2020. Thus far we have 
encountered fewer cardiac complications than we initially anticipated, although our case studies 
below show these do occur. In this review, we therefore examine what cardiac complications may 
occur, how frequent these are, and highlight the many uncertainties about the cardiac risks of 
COVID-19.
Coronaviruses and heart disease
Coronaviruses were described in 1965 as a cause of the common cold (19, 20) and cause a 
substantial proportion of respiratory tract infections globally. Until the present millennium, 
coronaviruses were believed to cause mild self-limiting disease (21). However, the recognition 
that viruses, including coronaviridae, can affect the heart is not new. A link between viral infections 
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and inflammation of the pericardium (pericarditis) (22), myocardium (myocarditis) (23, 24) and 
impaired ventricular function and heart failure due to cardiomyopathy (25) has long been 
recognized. Although coronaviridae were occasionally linked to these diseases before 2003, 
coxsackie, adenovirus, enteroviruses, human immunodeficiency virus (HIV), and influenza have 
been far more frequently associated with cardiac complications. Since viral testing (especially 
histologically on cardiac biopsy or at autopsy) is rarely performed clinically, even in severe cases, 
and never in mild community-based disease, the true incidence of viral or post-viral cardiac 
complications following coronavirus or other viral infections is poorly understood. It is therefore 
possible that non-COVID coronaviruses are associated with a greater proportion of cardiac 
disease than previously appreciated.
Cardiac complications of SARS and MERS
In 2003, coronavirus SARS-CoV1 was responsible for “the first new infectious disease of the 21st 
Century” (26); Severe Acute Respiratory Syndrome (SARS). SARS was associated with over 
8000 cases worldwide and 774 deaths, representing a case fatality rate of 9-15% (27, 28). Both 
SARS-CoV1 and SARS-CoV2 use cell-surface angiotensin converting enzyme 2 (ACE2) to enter 
the host cell (29, 30). It might be expected, therefore, that COVID-19 and SARS may share a 
similar pattern of cardiac complications.
Despite its high mortality, SARS does not appear to have been associated with a notably high 
rate of direct cardiac complications. There are few reports of fulminant or severe cardiac 
complications with SARS, although postmortem evidence shows multisystem involvement, 
including small venous thrombosis (31). In 121 patients with SARS, a high rate of hypotension 
and tachycardia was reported (32). One patient had paroxysmal atrial fibrillation and one patient 
developed mild left ventricular dysfunction in the context of severe pneumonia requiring inotropic 
support. Persistent tachycardia has been reported (33). Although case series of cardiac arrest 
exist (34), this does not in itself confirm direct cardiac effects in a disease with a high fatality. In 
46 SARS patients (14 mechanically ventilated) studied by serial echocardiography, one patient 
(a 39 year-old woman) had severe left ventricular systolic impairment and died, although with no 
postmortem evidence of either infarction or myocarditis. The remaining patients showed a slight 
reduction in diastolic LV function compared to the assessment after recovery, but this does not 
confirm direct myocardial suppression.
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It is unclear whether the rate of cardiac complications in SARS is comparable to that seen in 
COVID-19, as case numbers of SARS were far lower and sensitive cardiac markers to detect 
myocardial damage such as troponin were not widely available in 2003. The rapid recognition of 
cardiac manifestations seen with COVID-19 suggests SARS-CoV2 may have a greater propensity 
to cause these than SARS-CoV1 though this is far from definite and may relate more to wider 
accessibility of serum cardiac-specific troponin assays (a highly sensitive marker of myocardial 
necrosis) and cardiac imaging, including point-of-care echocardiography. What is clear is that pre-
existing cardiac conditions such as diabetes and hypertension, as well as older age significantly 
increase the risk of mortality or adverse outcome in SARS (35-38). This pattern of susceptibility 
appears to be shared with both MERS (see below) and COVID-19.
The coronavirus MERS-CoV was responsible for the Middle East Respiratory Syndrome (MERS) 
that arose in Saudi Arabia in 2012. MERS is still present, so far causing 858 deaths from 2494 
confirmed cases (case fatality rate 34%). Several sources state MERS may cause myocarditis, 
although we find only one case report (39) and no systematic estimate of myocarditis incidence. 
This complication is therefore probably low, although, like SARS, a lack of widespread troponin 
testing may have masked its prevalence. A characterization of 47 MERS cases described no 
cardiac complications despite 60% mortality (40). There is a single case report of MERS 
presenting with pericarditis (41), although the distinction between the pain of pericarditis and chest 
infection is challenging and it is not uncommon to encounter diagnostic uncertainty. A second 
case of “pericarditis” associated with MERS has been cited (14) but the MERS infection was 
actually acquired in ITU after surgical pericardiectomy (41).
Overall, like SARS, MERS does not appear to be associated with high rates of direct cardiac 
complications, although the low number of cases and high fatality rate in both diseases makes it 
impossible to conclude this definitively. MERS-CoV uses the dipeptidyl peptidase 4 receptor to 
gain entry to the host cell, raising the possibility that this different mode of pathogenesis may 
underlie a lower risk of direct cardiac complications compared to COVID-19. Despite little 
evidence of direct cardiac complications with MERS, as with SARS the rate of cardiac co-
morbidity in severe MERS was high with either diabetes and/or hypertension which were present 
in almost 50% in a metanalysis of 637 patients (42).
Cardiac complications in COVID-19: Case studies
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Case 1: Myocardial injury and thrombosis
A 61-year-old male patient with hypertension and epilepsy was referred to our primary 
percutaneous coronary intervention (PCI) service as a possible ST-elevation myocardial infarction 
after a 4-day history of malaise and diarrhoea followed by sudden onset pleuritic chest pain. 
Electrocardiogram showed right bundle branch block with anterior and lateral ST-segment 
elevation. Chest x-ray (CXR) showed bilateral patchy consolidation (Figure 1A) and SARS-CoV2 
RNA PCR was positive on a nose-throat swab. Arterial blood gas showed type 1 respiratory failure 
and echocardiogram showed severe left ventricular (LV) systolic impairment (LV ejection fraction 
30%) with severe septal, anterior and apical hypokinesis and a large 19 x 14mm thrombus 
adherent to the moderator band within the right ventricular apex (Figure 1B). He was managed 
with intravenous unfractionated heparin infusion, supplementary oxygen and intravenous 
antibiotics. Computed tomography pulmonary angiography (CTPA) and left heart catheterisation 
were planned but he deteriorated suddenly and died before this was performed.
Case 2: Pulmonary embolism
A 34-year-old with a past medical history of obesity and type 2 diabetes mellitus was admitted 
with increasing shortness of breath and 11-day history of dry cough and associated pleuritic chest 
pain. SARS-CoV2 RNA PCR was positive on a nose-throat swab.  Electrocardiogram was normal.  
CTPA (Figure 2) showed bilateral acute pulmonary embolism and patchy bilateral airspace 
consolidation. The patient was anticoagulated with rivaroxaban and treated with oxygen. The 
patient recovered and was discharged.
Case 3: Minor cardiac damage in mild COVID-19
A 48-year-old hypertensive male patient of Afro-Caribbean ethnicity was admitted with cough and 
pyrexia but a normal CXR. SARS-CoV2 RNA PCR was positive on a nose-throat swab. He was 
treated with antibiotics but developed some pleuritic chest pain. His cardiac troponin level was 
mildly elevated, but echocardiography was normal. He recovered well and was discharged.
Relationship between cardiovascular risk factors and severity of COVID-19
As with MERS and SARS, the severity of COVID-19 is increased in patients with higher 
cardiovascular risk. Factors such as male sex, older age, systemic hypertension, diabetes, 
obesity and established cardiovascular disease appear to make the patient particularly vulnerable 
to both morbidity and mortality. 
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(43). A UK study reported an overall mortality rate of 33% in 16,479 patients with COVID-19 (16% 
of all confirmed UK cases at that time). The mortality of patients on mechanical ventilation was 
over 50% even though ventilated patients were younger than the average (61 versus 72 yr). In 
this study, age, obesity, male sex and comorbidities, including chronic cardiac disease, were 
independently associated with higher mortality (44).
Myocardial injury and COVID-19
Myocardial injury is commonly reported in COVID-19, identified as an elevation in serum troponin. 
In early case series from Wuhan, 12% of patients had raised serum troponin levels suggesting 
acute myocardial injury (45). In another series, 7% of 138 admitted COVID-19 patients had 
elevated troponin levels, including 22% in ICU patients but only 2% of non-ICU-treated patients 
(46). Elevated serum troponin is associated with much higher risk of death; in two other series, 
the rate of cardiac injury in admitted patients was 20-28%, which was associated with 51-59% 
mortality compared with 4-9% mortality in those with normal troponin (47, 48). In addition, the rate 
of mechanical ventilation was substantially higher in those with cardiac injury (48). The 
association between myocardial injury and ventilation (primarily used for inadequate oxygenation 
rather than cardiac failure) suggest that overt myocardial injury in the absence of severe 
respiratory COVID-19 complications is relatively uncommon. However, as case 3 shows, it is 
possible for even very mild COVID-19 to be associated with detectible cardiac injury.
The mechanisms for myocardial injury in COVID-19 remain incompletely understood. A number 
of possible mechanisms are proposed but myocardial injury is likely to be multifactorial in a 
heterogenous population that includes those with pre-existing coronary artery or myocardial 
disease. Myocardial injury can result from thrombosis (see below). Other putative mechanisms 
include both direct effects of the virus on the myocytes, potentially mediated by the ACE2 
receptor, or indirect effect of the infection due to the systemic inflammatory response (49). 
Myocarditis is defined as an inflammatory condition of the myocardium and is most commonly 
caused by viral infection in Europe and North America but may also be immune-mediated (50). It 
has been suggested that the myocardial injury seen in COVID-19 may be due to a direct viral 
myocarditis (11, 51), however definitive evidence for myocardial viral infection is not yet available. 
Myocarditis can be challenging to diagnose and is often reliant on clinical features and histological 
analysis of an endomyocardial biopsy (EMB). In the small number of published cases with 
significant myocardial dysfunction (clinical myocarditis) associated with COVID-19 who had EMB, 
there were no characteristic histological features. A single case from Italy has shown viral 
inclusion bodies within EMB samples but without myocyte necrosis and only low-grade 
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inflammation (50). Overall, although the cardiac injury in COVID-19 is likely to relate to many 
factors, it seems likely that direct myocarditis does occur in at least a proportion of those cases 
with elevated cardiac markers and profound cardiac dysfunction in the absence of pre-existing 
cardiac disease, although the prevalence of such cases remains unknown. 
When evaluating the causes and incidence of cardiac injury in COVID-19, it is important to 
recognise that cardiac injury in any critically ill patient is very common. In community-acquired 
pneumonia, 85% of ventilated patients have cardiac injury (52) and elevated troponin is also 
associated with a substantially higher mortality in this context (53). This makes it likely that a 
substantial proportion of the cardiac injury seen in COVID-19 is not related to SARS-CoV2-
specific mechanisms and more related to critical illness.
An epidemic in which myocardial injury is a major component raises concern that, after recovery 
from the acute illness, some patients may develop left ventricular impairment and heart failure as 
a post-infective cardiomyopathy. So far, there are no longer-term follow-up studies of cardiac 
function, but the time-course of persistent troponin elevation and any cardiac dysfunction will be 
important to define.
Thrombosis in association with COVID-19
The relationships between inflammation and thrombosis are well recognised (54) and so it is 
expected that patients with dysregulated inflammatory response in COVID-19 will have an 
associated prothrombotic state. However, COVID-19 is associated with a prothrombotic disorder 
that appears more severe even than other critical illnesses. D-dimers are generated during fibrin 
breakdown, the essential constituent of thrombi, and early reports from China show raised D-
dimer levels in COVID-19 patients (55). In patients with severe COVID-19, survivors had lower 
D-dimer levels whilst a progressive elevation of D-dimer was associated with poor prognosis (56). 
The use of heparin thromboprophylaxis was associated with a survival advantage in patients with 
markedly raised D-dimer (57). Initially it was suggested this elevated D-dimer reflected 
disseminated intravascular coagulation (DIC), but this is not the case as the fibrinogen and 
platelet count remain normal until very late in the disease (58). Indeed, we have demonstrated 
that D-dimer is elevated in the acute inflammatory response to sterile endotoxaemia without 
evidence of the classic DIC of fulminant infection (59)
In keeping with the laboratory findings in COVID-19, clinical data has confirmed a very high 
thrombotic risk. An early report suggested that the incidence of pulmonary emboli amongst 
patients with COVID-19 in ITU was 20% despite most receiving antithrombotic treatment (60). An 
initial description of a cohort of 184 COVID-19 ITU patients suggested the rate of thrombotic 
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complications was 31% (61) which was later updated to an even higher rate (49%) of venous 
thromboembolism (VTE), 87% of which were pulmonary emboli (PE) (62)
The prothrombotic state in COVID-19 may partly relate to endothelial cell damage. Endothelial 
cells express ACE2 on their surface. Damage to endothelial cells by infection (termed endotheliitis 
(63)) results in transformation of the microvascular environment from anti- to pro-thrombotic. 
Although the exact mechanism remains unclear, there is a major increase in procoagulant factors 
such as factor VIII and von Willebrand factor. Concurrently, the levels of plasminogen activator 
inhibitor 1 (PAI1) are also increased, resulting in inhibition of fibrinolysis(64). These changes in 
the alveolar microenvironment result in microthrombi leading to impaired perfusion and poor 
oxygen exchange. The micro-thrombotic process has been termed pulmonary intravascular 
coagulation (PIC) to distinguish it from the more widespread process of DIC (65). Microvascular 
thrombosis and endothelial damage in COVID-19 may however also link this complication to 
myocardial injury due to ischaemia as well as an increased risk of stroke (66, 67). Indeed, the 
high frequency of thrombotic complications in COVID-19 may provide a more likely explanation 
of myocardial injury than both direct viral invasion of the myocardium or the impact of inflammatory 
response to COVID-19 on the myocardium, as discussed above.
The number of PEs reported in ICU COVID-19 patients is much higher than with lower limb DVT. 
It is usually considered that PE results from clot originating in a lower limb DVT that embolises to 
the lungs. The observation there are widespread pulmonary microthrombi and PE with a paucity 
of DVT in COVID-19 led to the suggestion that what is observed is pulmonary thrombosis 
generated in situ in the pulmonary arteries rather than PE (68, 69). This may be of clinical 
importance as therapeutic anticoagulation is efficient in treating DVT and PE, but may be less 
effective in treating pulmonary thrombosis.
Due to the prothrombotic nature of COVID-19 infection, all patients admitted to hospital should 
receive thromboprophylaxis with low-molecular-weight heparin (LMWH), unless there is a 
contraindication such as severe thrombocytopenia. The high thrombotic rates in ITU patients, 
despite LMWH thromboprophylaxis, has led many to increase the thromboprophylactic dose to 
twice daily. Some have gone further and use full-dose anticoagulation in all patients admitted to 
ICU with COVID-19. A recent observational study of 2773 patients suggested that anticoagulation 
was associated with lower mortality in the 395 patients who were ventilated, although this must 
be interpreted with caution due to several potential confounders (70). Many randomised trials of 
different doses of LMWH are ongoing so hopefully the evidence will be generated soon. 
When comparing COVID-19 patients with other critically ill patients, COVID-19 does seem to 
present a higher thrombotic risk. A comparison of 150 COVID-19 ICU patients with a group of 
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matched non-COVID-19 ICU patients with Acute Respiratory Distress Syndrome (ARDS) 
observed a 2.6-fold higher risk of VTE and 6.2-fold higher risk of PE in the COVID-19 group (71). 
Most of the thrombotic events were venous but a 2.6% arterial thrombosis rate also occurred. 
Arterial thrombosis in COVID-19 has been reported even in the absence of underlying 
atherosclerosis or other predisposing conditions (72), a possible pointer to the role of thrombosis 
as a potential mechanism for myocardial injury.
Cardiac Arrhythmia and COVID-19 
The incidence of arrhythmia in cases of COVID-19 has been reported to be 5-17%(47, 73, 74) 
with higher rates (44%) in patients requiring intensive care (46). By far, sinus tachycardia is the 
most common, consistent with most systemic illnesses. Other forms of arrhythmia range from 
relatively benign supraventricular and atrial arrhythmias to ventricular arrhythmia and cardiac 
arrest. It is unsurprising that those with severe COVID-19 are more prone to arrhythmia due to 
indirect effects including hypoxia, septic shock, multi-organ failure and metabolic and electrolyte 
abnormalities (75). In keeping with this, the majority of cardiac arrests complicating COVID-19 
result in non-shockable rhythms (PEA or asystole) and are likely to be respiratory (or pulmonary 
embolic) in origin (76). Furthermore, those patients with established or undiagnosed 
cardiovascular disease are more prone to arrhythmia in response to any illness due to induced 
ischaemia and/or myocardial injury. In patients with less severe illness or those who recover from 
COVID-19, the risk of arrhythmia is unknown.
There have been reports of COVID-19 patients experiencing QT prolongation (QTc > 500ms) 
leading to episodes of polymorphic ventricular tachycardia (Torsades de Pointes). Such QT 
prolongation has been linked to medication, including treatments for COVID-19, 
hydroxcholroquine and azithromycin, and is reversible on stopping the drug (77). Brady-
arrhythmias have been described less frequently, although there are a number of reported cases 
of sinus node dysfunction, possibly caused by myocardial inflammation of the sino-atrial node(78).
Paediatric Multisystem Inflammatory Syndrome and Kawasaki’s disease
Unlike other viral pandemics such as influenza, children and young adults appear far less likely 
to suffer severe COVID-19, representing only 1-2% of admitted patients (79). However, reports 
have emerged of a “Paediatric multisystem inflammatory syndrome” in association with SARS-
CoV2 infection. The European Centre for Disease Prevention and Control describes around 230 
cases in the EU and UK with two deaths, although not all of these were confirmed to have COVID-
19 (80). This condition appears to overlap with Kawasaki’s disease, a vasculitis of unknown cause 
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that can cause hypotension, cardiac dysfunction and coronary artery aneurysms, which may 
present with myocardial infarction or rupture (81). A recent report of a 30-fold increased incidence 
of Kawasaki’s type response in the COVID-19 epicentre of Northern Italy (82, 83) raises the 
possibility that SARS-CoV2 acts as a trigger for this disease, with the potential for an increase in 
the acute and late cardiac complications seen with this condition.
Conclusions
COVID-19 is associated with a high rate of detectible cardiac injury and a higher risk of thrombosis 
than similar critical illnesses. However, our fears of a large number of severe cardiac 
complications of COVID-19 have so far not materialized. It remains to be seen whether longer 
term cardiac complications manifest as we follow up surviving patients and gain more experience 
with this new disease.
The numerous social restrictions and reallocation of healthcare resource towards combatting 
COVID-19 are unfortunately likely to themselves cause a significant number of deaths and 
morbidity as routine and emergency healthcare is compromised. Reports from Italy suggests a 
reduction in the presentation of myocardial infarction during the epidemic by 26%-30% with 
corresponding increase in mortality (84-86). A decrease in STEMI incidence during COVID-19 
has also been noted in Northern Europe(87). We have seen this pattern repeated in our own 
service as patients are asked (overtly or subliminally) to triage and manage their own conditions 
without the necessary expertise and support. The cardiac effects of COVID-19 will not therefore 
be borne only by those who have contracted the disease and will be challenging to quantify for 
many years.
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Figure Legends
Figure 1: COVID-19 presenting with chest pain and right ventricular thrombosis. A: Chest 
X-Ray showing typical patchy opacities throughout both lungs and normal cardiac sillhouette. B: 
Series of echocardiographic images demonstrating RV thrombus.  On the annotated images on 
the bottom row, the thrombus is highlighted in yellow, the right ventricle in blue and the left 
ventricle in red.
Figure 2: COVID-19 presenting with pulmonary emboli. Computed tomography pulmonary 
angiography showing bilateral acute pulmonary emboli (unfilled arrows) and bilateral patchy 
airspace consolidation (filled arrow). 
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Figure 1: COVID-19 presenting with chest pain and right ventricular thrombosis. A: Chest X-Ray showing 
typical patchy opacities throughout both lungs and normal cardiac sillhouette. B: Series of echocardiographic 
images demonstrating RV thrombus.  On the annotated images on the bottom row, the thrombus is 
highlighted in yellow, the right ventricle in blue and the left ventricle in red. 
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Figure 2: COVID-19 presenting with pulmonary emboli. Computed tomography pulmonary angiography 
showing bilateral acute pulmonary emboli (unfilled arrows) and bilateral patchy airspace consolidation (filled 
arrow). 
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